Peeyush Shrivastava

The list of fellows published by the Thiel Foundation in 2017 gives his hometown as “Kuala Belait, Brunei / Mason, OhioOhioOhio is a state in the Midwestern United States; its capital is Columbus. It joined the Union in 1803 as the 17th state, the first carved from the Northwest Territory, and its population in the 2020 census (April 1, 2020) was 11,799,448.Open the full entry.”⁠[1]

He grew up in Mason, Ohio, together with Vineet Erasala and Manny Setegn, who later co-founded Genetesis with him. He said: “We grew up friends in Mason, and we knew we wanted to build something together.” The Project Medtech episode description calls the three friends from middle school.⁠[2][3]

Society for Science’s 2017 profile states that he was a 2013 Intel Science Talent Search semifinalist. He said that he first became interested in STEM through independent research on bioelectricity: “In middle school, I started reading open source material on pacemaker activity in the heart,” and on conduction abnormalities; the profile states that this fascinated a young man who had only ever thought of the heart as a mechanical pump for blood. He said: “The Science Talent Search is a platform for excellence.”⁠[4]

He attended Mason High School. WCPO’s 2016 report states that while classmates played video games, he and a few fellow students were investigating bioelectricity, an interest he took up after his grandfather was diagnosed in 2006 with several neurological conditions. REDI Cincinnati’s 2017 article states that he and his friends learned at Mason High School to measure the electrical currents of heart cell samples.⁠[5][6]

REDI Cincinnati’s 2017 article states that the founders grew up in Cincinnati’s biotech corridor, watching industry giants such as Assurex Health and AtriCure grow there.⁠[6]

Genetesis was founded in Mason, Ohio, in 2013. WCPO’s report states that he, Vineet Erasala and Manny Setegn, three young men, started the company in 2013 together with his father, Chandan Srivastava.⁠[7][5]

COSE’s 2023 article states that the three founders were very young when the company began: two were still in high school and the other had just graduated. He said that they started the company before deciding what it would build, and by 2016 they had settled on a cardiology product.⁠[2]

REDI Cincinnati’s article states that he pitched the idea for the startup to a group of friends the summer before he started at Ohio State UniversityOhio State UniversityOhio State University (officially The Ohio State University) is a university in Columbus, Ohio, United States, established by the state legislature in 1870.Open the full entry. BioSpace’s 2016 article states that he describes himself as a tinkerer; in early research he saw many medical uses for measuring the heart’s electrical currents directly, found that no clinical method for it existed, believed one was possible, and worked on the problem with friends from Mason High School, who became his co-founders.⁠[6][8]

The 2023 Project Medtech episode description states that he founded the company with two other friends from middle school and that the three dropped out of college together.⁠[3]

In late 2014 Genetesis was a finalist at 43North in Buffalo, New York, winning $250,000, which it used for a prototype and clinical trials. WCPO’s report states that the money also allowed him to take leave from Ohio State University and spend all his time on Genetesis. BioSpace’s 2016 article lists 43North as one of the company’s five investors.⁠[5][8]

WCPO’s report states that his interest in bioelectricity led him to create Genetesis’s proprietary mapping system in early 2015.⁠[5]

He said that in May 2016 Mark CubanMark CubanMark Cuban is an American entrepreneur and investor whose early work in computer systems and internet audio and video expanded into sports, film, venture investment and pharmaceuticals. He was the Dallas Mavericks’ controlling owner and a longstanding investor on Shark Tank, and co-founded Mark Cuban Cost Plus Drug Company.Open the full entry invested $350,000 in Genetesis. BioSpace’s article states that he reached Mark Cuban with a cold email, sent, he said, “Right to his personal Gmail account”; he said that Mark Cuban first came on as an adviser, wanting to see how to generate clinical interest, and then saw an opportunity to invest.⁠[5][8]

WCPO’s report of October 29, 2016 states that Genetesis was based in Over-the-Rhine, Cincinnati, where its five full-time employees, the three founders included, normally worked at Union Hall; its engineering staff worked in Columbus, where most of its clinical trials took place, and it planned to hire five more people, mostly engineers, by the first quarter of the following year.⁠[5]

The report describes the prototype as a mobile device on wheels with a long arm placed over the patient’s chest; he called it “kind of the opposite of an MRI,” since it measures a magnetic field rather than emitting one. He declined to say what the machines would cost; pending FDA approval, the company hoped to sell its first units in early 2018 while clinical trials continued. Of running the company he said: “That’s a humbling feeling.”⁠[5]

The report states that the company’s advisory board was large and that most of its members were much older than he, Vineet Erasala and Manny Setegn, whom it describes as “all 30”; Alisa Niksch, director of the pediatric electrophysiology and exercise stress lab at Tufts Medical Center, received a stake in exchange for her expertise, and he first reached out to her through LinkedInLinkedInLinkedIn is a social networking platform for professionals. It was founded in 2002 by Reid Hoffman and others, launched in 2003, and listed on the New York Stock Exchange in 2011; after Microsoft acquired it for approximately $26.2 billion in 2016, it became a wholly owned Microsoft subsidiary. Its revenue comes from membership subscriptions, advertising, and recruitment solutions.Open the full entry.⁠[5]

On November 14, 2016 Genetesis announced a $1.2 million seed round co-led by CincyTech and Mark Cuban’s Radical Investments, with participation from LOUD Capital, Danmar Capital, Wilson SonsiniWilson Sonsini Goodrich & RosatiWilson Sonsini Goodrich & Rosati (known as Wilson Sonsini) is a law firm headquartered in Palo Alto, California, founded in 1961 and known for serving technology, life sciences, and other growth companies and their investors; it served as counsel on the initial public offerings of companies including Apple, Netscape, Google, and Tesla. As of December 2025 the firm had more than 1,000 lawyers, and its 2025 revenue was $1.4 billion.Open the full entry Investment Company, Genetesis management and private angel investors; the company then had ten employees and planned to use the money to scale engineering, launch clinical studies and seek FDA regulatory clearance. The release describes CardioFlux as a medical device that maps the heart’s electrical activity in three dimensions to help diagnose and guide treatment of conditions such as ischemia, atrial fibrillation and ventricular tachycardia. Mark Cuban says in the release that the Genetesis technology opens broad new commercial markets for what had for decades been primarily a research tool.⁠[7][9]

The release states that he would present data collected in collaboration with the Mayo Clinic at the American Heart Association Scientific Sessions on November 15. He said: “These results demonstrate promising improvements for the noninvasive detection of ischemia in patients with high-risk chest pain, as compared to tools available in the emergency room today.”⁠[7][9]

BioSpace’s profile of December 12, 2016 states that Peeyush Shrivastava, the founder of Genetesis, turned 21 that month; REDI Cincinnati’s article of July 3, 2017 likewise calls him the company’s 21-year-old founder and chief executive.⁠[8][6]

The article states that Genetesis, then based in Cincinnati, had raised $1.46 million in two rounds from five investors, Mark Cuban, Loud Capital, Danmar Capital, CincyTech and 43North, and that the Mayo Clinic was involved in data collection using CardioFlux. It calls CardioFlux a next-generation electrocardiogram and states that the Genetesis CardioFlux Mapping System uses the body’s weak magnetic fields to reconstruct areas of high and low electrical conductivity in the heart. He would not name the hospitals in talks about clinical trials, saying only that there was interest and negotiations were under way. The company’s advisers came from Tufts Medical Center Pediatrics, Advanced Cardiovascular Specialists in Mountain View, CaliforniaCaliforniaCalifornia is a U.S. state on the Pacific coast; its capital is Sacramento and its largest city is Los Angeles. California was admitted to the Union on September 9, 1850, as the 31st state. Its population at the 2020 Census (April 1, 2020) was 39,538,223, the largest of any state.Open the full entry, Texas A&M University, The University of Alabama System and the Biomagnetism and Clinical Physiology International Center (BACPIC) in Rome.⁠[8]

The article quotes his interview with Cincinnati.com: he said that he likes being an entrepreneur and is drawn to big ideas that improve human life, and he called the Genetesis technology a platform technology that could apply to any organ with an electrical current.⁠[8]

Society for Science’s profile of May 9, 2017 describes him as the CEO of Genetesis, a cardiac imaging company, and states that he was a BioOhio startup winner and had been nominated as one of the “top AI startups for social impact,” and that Genetesis won seed funding from Shark Tank’s Mark Cuban. He said: “Our system is completely radiation-free, and a scan takes under 90 seconds.” He said that patients with non-cardiac chest pain could be ruled out far more quickly and cheaply and that the company could determine whether a patient would benefit from a stent; “Our tagline ‘science made personal’ is somewhat of our mission statement.” He also said: “The first and hardest step in STEM is realizing that you must take the initiative to learn.”⁠[4]

On June 16, 2017 the Thiel Foundation named the 25 members of the 2017 class of Thiel Fellows, and he was among them (item 17 of the list, spelled “Peeyush Shirvastava”). The announcement states that the two-year Thiel Fellowship provides young entrepreneurs with $100,000 and mentorship from the Thiel Foundation’s network of technology entrepreneurs, investors and scientists, and that the program, launched in 2011, encourages fellows to pursue full-time entrepreneurship instead of going to college. The list places him under “Medical Device,” with the project Genetesis, and describes him: “Peeyush is CEO of Genetesis, a medical device company that developed CardioFlux, an imaging platform that leverages next-generation sensors and advanced computing to noninvasively measure and analyze the heart's natural magnetic fields.”⁠[1][1]

COSE’s 2023 article states that he pursued his startup as a Thiel Fellow. His profile page on the University Innovation Fellows website lists him as a Thiel Fellowship finalist.⁠[2][10]

REDI Cincinnati’s article of July 3, 2017 states that Genetesis, started by three part-time founders, had raised $1.5 million in seed-stage funding, including from Mark Cuban, and was developing technology that uses artificial intelligence and 3D imaging to identify and diagnose abnormal activity in the heart; the founders could have located anywhere but chose to return to Mason after college, and the article expected the company to have 26 full-time employees a year later.⁠[6]

He called his team a “scrappy little team,” said that the best thing they did was to talk to local business people, who helped them identify what exactly they were building and that in health care “you need to constantly learn from your stakeholders and your customers,” and said that CincyTech’s director of life sciences, John Rice, “was willing to hear us out” before the company had a business plan. The article states that he hoped the company’s return to Mason would show investors and future workers that the Cincinnati region is “an exciting place to create new ideas and start successful careers.” Genetesis was later located in the Tech Elevator in Mason’s bio hub.⁠[6][11]

On June 5, 2018 Genetesis announced an oversubscribed $7.5 million Series A round led by CincyTech, with existing investor Mark Cuban’s Radical Investments and new investors Ohio Innovation Fund and Raptor Group; the money was to build and install more CardioFlux systems, launch new clinical trials and prepare for commercial launch. The release states that the biomagnetic imaging technology is passive and noninvasive, requires no radiation or exercise, and with proprietary software detects ischemic cardiac tissue in a 60- to 90-second scan; a 100-patient, double-blinded clinical study completed at St. John Hospital was presented in May by Margarita Pena, director of the Clinical Decision Unit at St. John Hospital in Detroit, MichiganMichiganMichigan is a state of the United States nearly surrounded by the Great Lakes and made up of the Upper and Lower peninsulas; its capital is Lansing and its largest city is Detroit. It was admitted to the Union on January 26, 1837, as the 26th state, and its population in the 2020 census (April 1, 2020) was 10,077,331.Open the full entry, at the Society of Academic Emergency Medicine Annual Conference, and the chief medical officer, Alisa Niksch, presented key data at the Society for Cardiovascular Angiography and Interventions.⁠[12][13]

He says in the release: “Our goal is to give clinicians an accurate and easy-to-operate tool,” sparing patients and hospitals the discomfort and expense of invasive and lengthy testing. MD+DI states that the company had earlier raised a $1.5 million seed round at the end of 2016 and about $500,000 in grants and non-dilutive funding, and planned to submit for FDA clearance the month after the article appeared; he said that unlike an MRI the technology is passive: “We’re actually visualizing the function of the heart.” MedCity News quotes him in 2017 saying that the technology has a high negative predictive value, “giving physicians the ability to rule out cardiac-origin chest pain, very quickly, without any invasiveness.”⁠[12][14][13]

On March 22, 2019 Genetesis announced FDA 510(k) clearance for its cardiac imaging platform, which pairs the CardioFlux magnetocardiograph with the integrated Faraday Analytical Cloud. The release states that CardioFlux uses optically pumped magnetometers, removing the need for liquid-helium cooling, and sends data securely to the cloud for physicians to review; John Rice, CincyTech’s director of life sciences, was chairman of the Genetesis board, and the West Virginia University Heart and Vascular Institute was implementing the CardioFlux system.⁠[15]

MedTech Dive states that the test is meant for emergency physicians and cardiologists evaluating chest-pain patients for coronary artery disease and myocardial ischemia, that a scan takes under 90 seconds, and that cloud-based AI produces a clinical report within five minutes; a prototype had been tested in a 101-patient study at Ascension St. John Hospital in Detroit.⁠[16]

On August 26, 2019 Genetesis announced that Peter Donato had joined as chief business officer. He says in the release, “We're thrilled to bring Peter onto the team,” and that the company’s recent FDA 510(k) clearance, CMS reimbursement and ongoing hospital installations “mark only the beginning” of its aim to optimize chest-pain triage for patients and physicians in emergency departments throughout the United StatesUnited StatesThe United States is a federal country in North America made up of 50 states, the District of Columbia as the seat of government, and territories such as Puerto Rico and Guam; its capital is Washington, D.C. The Continental Congress adopted the Declaration of Independence on July 4, 1776. The 2020 census (April 1, 2020) counted a resident population of 331,449,281, and the 435 seats of the House of Representatives are apportioned among the states on the basis of the census.Open the full entry.⁠[17]

In December 2020 Genetesis announced that the FDA had granted CardioFlux Breakthrough Device designation for diagnosing myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome. The release describes CardioFlux as a magnetocardiograph that uses room-temperature magnetometers to measure the heart’s magnetic fields noninvasively in a 90-second, radiation-free test with no pharmaceuticals or intravenous radioactive contrast; it had been cleared by the FDA in 2019 as a general tool for measuring and displaying the heart’s magnetic signals, and the company expected widespread clinical use in 2021.⁠[11][18]

In October 2022 Genetesis announced a $17.5 million Series C round led by Mithril Capital, with new investor Cercano Management and existing investors JobsOhio Growth Capital, Ohio Innovation Fund and CincyTech, bringing its total funding to more than $40 million. The release states that the money would launch a five-minute noninvasive ischemia assessment requiring no pharmaceuticals, exercise or radiation, and that the ACCMED trial with Cleveland Clinic, Ascension St. John, Wake Forest Baptist Health and Beaumont Royal Oak Hospital was in its final month of primary enrollment. He says in the release: “We have made it our mission to manifest the convergence of computing, sensing and medical imaging,” in order to deliver the most cost-effective and patient-centric solution for cardiovascular disease. BioWorld wrote on October 7, 2022 that the round nearly doubled the company’s total funds raised, to $40 million.⁠[18][19]

On January 9, 2023 the podcast Project Medtech released an episode titled “Episode 122 | Peeyush Shrivastava, Founder and CEO at Genetesis | $35.7M Raised So Far: Middle School Friends Drop Out of College and Start a Medtech Startup Company,” in which he talks with Duane Mancini; the description says the conversation covers the rise of magnetocardiography, how the company raised money from Mark Cuban, the support of CincyTech and a problem-centric approach.⁠[3]

On January 19, 2023 Genetesis announced the appointment of Robert Takla as chief medical officer, Mazen Albaghdadi as vice president of medical affairs and Kevin Hillsman as vice president of market access, to oversee commercialization and clinical research for CardioFlux; the company expected FDA market authorization later that year. He says in the release, “As we inch ever closer to the FDA granting our De Novo request,” the expanded team is critical to the company’s next clinical and commercial milestones.⁠[20]

COSE’s article of April 18, 2023 states that he, Vineet Erasala and Manny Setegn were named to the Forbes Under 30 list for Genetesis. It states that he has a decade of experience as a medical technology entrepreneur and leads the company’s FDA approval and commercial launch; the chief operating officer, Vineet Erasala, studied electrical and biomedical engineering at Case Western Reserve University and oversees research and development, manufacturing and regulatory work; the chief technology officer, Manny Setegn, studied computer science and engineering at Ohio State University and took a leave of absence to lead technical development.⁠[2]

The article states that Genetesis, headquartered in Mason, had raised $40 million and had 30 employees, with plans for 40 by the end of the year; that week CardioFlux MCG received FDA Breakthrough Device designation, based on the MICRO trial with Cleveland Clinic, Christ Hospital in Cincinnati and Ascension St. John in Detroit, for identifying myocardial ischemia from coronary artery disease and coronary microvascular dysfunction; the company was also working with Cleveland Clinic on an emergency-room application in the MAGNETO trial, and its De Novo request was pending with the FDA. Early support came from CincyTech, JobsOhio and Ohio’s Third Frontier program. He said: “We are overjoyed and humbled to be included amongst this list of some truly incredible peers.” He also said that “Ohio is an excellent location for a health care startup,” with nearby hospitals as early adopters and trial sites and a deep talent pool from its universities.⁠[2]

On September 30, 2024 Genetesis announced that Health Canada had approved CardioFlux MCG for physicians to use as an aid in diagnosing myocardial ischemia, which the announcement calls the first approval of any kind of an MCG device in Health Canada history. He says in the announcement: “This is our first foray beyond the US, and we're excited to partner with physicians in Canada.”⁠[21]

On December 11, 2024 Genetesis launched the CardioFlux Membership Program, under which members visit CardioFlux Imaging Institutes regularly to track their myocardial fitness with a CardioFlux Score; its three plans, Starter ($349), Core ($499) and Pro ($999), differ mainly in the number of Scores measured per year, each Score comes with a consult by a board-certified physician, and the program is open to the public without a physician’s referral. The first CardioFlux Imaging Institute opened in Mason’s Biohealth Corridor, with a national rollout planned. The CardioFlux Score analyzes 14 biomarkers of the heart muscle’s electrical activity against a benchmark of healthy, symptom-free people; the company’s clinical-trial partners then included Cleveland Clinic, Hackensack Meridian Health, Mayo Clinic, Saint Luke's Health System, The Christ Hospital Health Network and the University of Florida.⁠[22]

He says in the release: “When we first began this company, we had dreamed of harnessing technology to actually prevent disease, not just detect it.” The release states that the company is headquartered just north of Cincinnati and has worked on MCG technology since 2013.⁠[22]

His profile page on the website of the Tim & Kathleen Keenan Center for Entrepreneurship at Ohio State University states that, as co-founder and chief executive of Genetesis, he raised more than $42 million and led the company from its founding in 2013 to its M&A in 2025. A 2026 article by Case Western Reserve University states that Genetesis raised more than $40 million from Midwest investors, including a seed round co-led by Mark Cuban, and that in late 2025 a strategic partner acquired the company’s core assets, closing a 12-year effort to take the device from concept to clinical use.⁠[23][24]

The O.H.I.O. Fund’s announcement “The O.H.I.O. Fund Accelerates into 2026” states that he joined the fund as a principal in January 2026 and describes him as a healthcare technology entrepreneur and the founder of Genetesis, recognized for pioneering noninvasive cardiac imaging innovations, who has led high-performance technical teams that bring medical technologies to market. The announcement states that The O.H.I.O. Fund is a private fund investment adviser based in Columbus whose legal entity is TOF Manager, LLC, co-founded by Mark Kvamme, its chief executive and chief investment officer, and Ray Leach, its co-founder and president, with two other founding partners, Jill Meyer and Mike Venerable.⁠[25]

As of November 2026, his profile page on the website of Ohio State University’s Keenan Center for Entrepreneurship gives him as a principal at The O.H.I.O. Fund, identifying and investing in promising companies and projects in Ohio, and states that he has more than 12 years of experience as a serial entrepreneur and technologist.⁠[23]

His profile page on the University Innovation Fellows website states that he was then a second-year student in the Undergraduate Biomedical Science Program at Ohio State University and a researcher there, recently named a University Innovation Fellow, in which role he worked to extend Ohio State’s innovation and entrepreneurship ecosystem through technical initiatives providing incubator support for student and faculty innovation. The page states that his research is in molecular biophysics and electrophysiology, that he has presented findings on the molecular mechanisms of cardiac arrhythmias across the country, and lists him as a General ElectricGE AerospaceGE Aerospace is the name under which General Electric Company operates, a jet engine maker listed on the New York Stock Exchange under the ticker GE.Open the full entry Star Award winner.⁠[10]

Sources differ on his studies at Ohio State University: BioSpace wrote in December 2016 that he was working on a degree in biomedical science there; WCPO wrote in October 2016 that he had taken leave from the university to work full time on Genetesis; COSE wrote in 2023 that he studied biomedical science there but left early; and his profile page on the website of Ohio State University’s Keenan Center for Entrepreneurship gives him a B.S. in Biomedical Science from the university.⁠[8][5][2][23]

His profile page on the website of Ohio State University’s Keenan Center for Entrepreneurship states that he was part of the founding team of Proscia, a digital pathology company that it says has raised more than $130 million and partnered with pharmaceutical companies and labs. His profile page on the University Innovation Fellows website lists him as co-founder and CSO of Proscia. The “Our founders” section of Proscia’s website names David West (chief executive officer), Coleman Stavish (chief technology officer) and Nathan Buchbinder (chief strategy officer) and does not name him. The Register wrote in 2015 that Proscia was founded in 2014 by five technologists, scientists and entrepreneurs from Johns Hopkins University, the Moffitt Cancer Center, the Ohio State University College of Medicine and the University of PittsburghUniversity of PittsburghThe University of Pittsburgh is a state-related research university in Pittsburgh, Pennsylvania, United States. It traces its origins to the Pittsburgh Academy, founded in 1787, and is one of the oldest institutions of higher education in the country.Open the full entry.⁠[23][10][26][27]

His father, Chandan Srivastava, was one of the people who started Genetesis; BioSpace’s 2016 article states that his father was then the company’s chief financial officer and describes him as a project manager of Business Solutions for “Generic Electric” (so spelled in the article).⁠[5][8]

His profile page on the University Innovation Fellows website states that his motivation comes from his grandfather’s experience of illness; his mission is personalized medical care for the masses, and he aims to give physicians and scientists data tools to help people facing similar conditions.⁠[10]

BioSpace’s 2016 article quotes his interview with Cincinnati.com: “I’m still driving the same hunk of junk that I’ve been driving for a while, a 1999 Avalon.” His profile page on the website of Ohio State University’s Keenan Center for Entrepreneurship states that he is an avid runner and cyclist.⁠[8][23]

Genetesis: Official website: https://www.genetesis.com/ (opens in a new window).⁠[28]

Proscia: Official website: https://proscia.com/ (opens in a new window).⁠[26]

Thiel Fellowship: Official website: https://thielfellowship.org/ (opens in a new window).⁠[29]